Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Recently, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication that warns of an increased risk of diabetic ketoacidosis (DKA) with uncharacteristically mild to moderate glucose elevations (euglycemic DKA [euDKA]) associated with the use of all the approved sodium-glucose cotransporter 2 (SGLT2) inhibitors (1).This Communication was based on 20 clinical cases requiring hospitalization captured between March 2013 and June 2014 in the FDA Adverse Event Reporting System database.The scarce clinical data provided suggested that most of the DKA cases were reported in patients with type 2 diabetes (T2D), for whom this class of agents is indicated; most likely, however, they were insulintreated patients, some with type 1 diabetes (T1D).The FDA also identified potential triggering factors such as intercurrent illness, reduced food and fluid intake, reduced insulin doses, and history of alcohol intake.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with either T1DM or T2DM taking insulin are at particular risk, with the greatest risk for ketoacidosis in T1DM.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [90]
In the citing paper
“Euglycemic ketoacidosis with minimal to no elevation in blood glucose levels may occur in patients taking SGLT2 inhibitors due to increased fatty acid oxidation and glucagon release along with decreased insulin secretion (89,90).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [90]
Citations
Cites
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 4×
“Thus, in SGLT2-treated T2D patients (17), the lower insulin-to-glucagon ratio stimulated lipolysis (circulating FFAs were ;40% higher during the meal) and enhanced lipid oxidation (by 20% on av-”
BackgroundInfluentialSelf-citationPeters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795 · cited 1×
“of the euglycemic insulin clamp, as a result of attenuated glucotoxicity (21).”
BackgroundInternational Textbook of Diabetes Mellitus
(2004) · Wiley eBooks · doi:10.1002/0470862092 · Cited by 725
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
Erondu, N., Desai, M., Ways, K., & Meininger, G. (2015) · Diabetes Care · doi:10.2337/dc15-1251 · Cited by 324
Euglycaemic Diabetic Ketoacidosis
Munro, J. F., Campbell, I. W., McCuish, A. C., & Duncan, L. J. P. (1973) · BMJ · doi:10.1136/bmj.2.5866.578 · Cited by 323
Insulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303 · cited 1×
“In contrast, plasma glucagon concentrations increased significantly, partly because of a diminished paracrine inhibition by insulin (18) and possibly also because of decreased SGLT2-mediated glucose transport intoa-cells (19).”
Background
Cited by
Items 201–300 of 685
Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease
Zonszein, J., & Groop, P. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0208-5 · Cited by 32
SGLT2-I in the Hospital Setting: Diabetic Ketoacidosis and Other Benefits and Concerns
Levine, J. A., Karam, S., & Aleppo, G. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0874-3 · Cited by 25
Park, J., Seo, I., Shim, H., & Cho, H. (2019) · Journal of Pineal Research · doi:10.1111/jpi.12623 · Cited by 25
Tsimihodimos, V., Filippatos, T. D., & Elisaf, M. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1258055 · Cited by 24
“and ketoacids in the collecting tubules [60,82].”
BackgroundGlucose Homeostasis, Pancreatic Endocrine Function, and Outcomes in Advanced Heart Failure
Melenovský, V., Beneš, J., Franeková, J., Kovář, J., Borlaug, B. A., Segeťová, M., Tura, A., & Pelikánová, T. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005290 · Cited by 24
Dapagliflozin‐Induced Acute Pancreatitis: A Case Report and Review of Literature
Sujanani, S., Elfishawi, M., Zarghamravanbaksh, P., Cuevas, F., & Reich, D. (2020) · Case Reports in Endocrinology · doi:10.1155/2020/6724504 · Cited by 24
“Adverse effects reported with this class of medications include genitourinary tract infections, urinary frequency, and rarely euglycemic diabetic ketoacidosis (DKA) [12, 13].”
Sampani, E., Sarafidis, P. A., & Papagianni, A. A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1764532 · Cited by 27
“As SGLT-2 inhibitors associated DKA may present with atypical features such as normal or moderately increased blood glucose levels, a high level of awareness would ensure early recognition and diagnosis [63].”
BackgroundASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE
Liew, A., Bavanandan, S., Prasad, N., Wong, M. G., Chang, J. M., Eiam‐Ong, S., Hao, C., Lim, C. Y., Lim, S. K., Oh, K., et al. (2020) · Nephrology · doi:10.1111/nep.13785 · Cited by 24
Garg, R., Sood, N., Bansal, O., & Hoskote, A. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-09073-2 · Cited by 27
Pharmacological management of type 2 diabetes: what’s new in 2017?
Scheen, A. J. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1376652 · Cited by 27
“Reduction in insulin dose, stimulation of the release of glucagon, and enhanced ketone re-absorption in the renal tubuli could contribute to the increase in the concentration of ketone bodies, whereas enhanced glucosuria limits the amplitude of hyperglycemia [80,81].”
BackgroundDiabetic Kinome Inhibitors—A New Opportunity for β-Cells Restoration
Pucelik, B., Barzowska, A., Dąbrowski, J. M., & Czarna, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169083 · Cited by 23
Kum-Nji, J. S., Gosmanov, A. R., Steinberg, H. O., & Dagogo-Jack, S. E. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.11.004 · Cited by 23
Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin
Adachi, J., Inaba, Y., & Maki, C. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.7501 · Cited by 24
“The possible mechanisms of this pathology are as follows: (1) her estimated glomerular filtration rate might have been increasing in association with early type 1 diabetes, thereby promoting glycosuria; (2) exogenous insulin may have augmented the effect of SGLT2 inhibition on glycosuria (13); and (3) canagliflozin de…”
BackgroundChiang, C., Lin, S.-Y., Lin, T., Wang, T., Yeh, H., Chen, J., Tsai, C., Hung, Y.-J., Li, Y., Liu, P., et al. (2018) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2018.01.001 · Cited by 22
“One should be aware that patients with SGLT-2 inhibitors related DKA may not have very high blood glucose level, sometimes being called “euglycemic DKA”, and their plasma glucose level is usually < 300 mg/dL.(228) In a systemic review, the average blood glucose on presentation of DKAwas 265.”
BackgroundKushner, P. R. (2016) · Women s Health · doi:10.2217/whe-2016-0001 · Cited by 22
Practical combination therapy based on pathophysiology of type 2 diabetes
LEVIN, P. A. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s109216 · Cited by 21
“1% for DKA was also reported from the clinical development programs for canagliflozin (N=17,596) and dapagliflozin (N>18,000).(132,135) The AACE has also under-”
InfluentialThe biochemistry of low-carbohydrate and ketogenic diets
Feinman, R. D. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000575 · Cited by 21
Kapila, V., & Topf, J. M. (2021) · Cureus · doi:10.7759/cureus.17093 · Cited by 30
“reviewed the US FDA Adverse Event Reporting System and uncovered that 71% of reported DKA cases with SGLT2i were euglycemic [12-13].”
BackgroundEuglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetes
Alduraibi, R. K., Alrebdi, Y. M., & Altowayan, Y. F. (2023) · Medicine · doi:10.1097/md.0000000000034027 · Cited by 21
The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes
Steen, O., & Goldenberg, R. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.08.241 · Cited by 23
A rare cause of metabolic acidosis: ketoacidosis in a non-diabetic lactating woman
SLOAN, G. P., Ali, A., & Webster, J. (2017) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-17-0073 · Cited by 21
Ketosis-Prone Type 2 Diabetes: A Case Series
Sjöholm, Å. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00684 · Cited by 23
Dapagliflozin-induced Late-onset Euglycemic Diabetic Ketoacidosis
Iqbal, I., Hamid, M., Khan, M. A. A., Kainat, A., & Tariq, S. (2019) · Cureus · doi:10.7759/cureus.6089 · Cited by 22
“Therefore, one of the main differences between eDKA and DKA is the renal glucose clearance (ratio of glucosuria to serum glucose), which can be twice as high in eDKA as in DKA [16].”
BackgroundGlucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Kuchay, M. S., Farooqui, K. J., Mishra, S. K., & Mithal, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_479 · Cited by 22
Xu, D., Chandler, O., Wee, C., Ho, C. L. B., Affandi, J. S., Yang, D.-Y. D., Liao, X., Chen, W., Li, Y., Reid, C. M., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.712671 · Cited by 22
Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Anderson, J. E., Wright, E. E., & Shaefer, C. F. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0211-x · Cited by 22
“Some—but not all—cases of ketoacidosis in patients on SGLT2 inhibitors have been atypical in that blood glucose levels are not as high as might be expected [50].”
BackgroundZurek, A. M., Yendapally, R., & Urteaga, E. M. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0030 · Cited by 23
“It may be precipitated by incomplete DKA treatment or reduced insulin dose, food restriction, alcohol consumption, or inhibition of gluconeogenesis (44).”
BackgroundArrieta, F., Iglesias, P., Pedro‐Botet, J., Becerra, A., Ortega, E., Obaya, J. C., Nubiola, A., Maldonado, G. F., Campos, M. D. M., Petrecca, R., et al. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.03.002 · Cited by 25
Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
Papakitsou, I., Vougiouklakis, G., Elisaf, M., & Filippatos, T. D. (2019) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s172353 · Cited by 29
Sodium Glucose Cotransporter 2 and Dipeptidyl Peptidase-4 Inhibition: Promise of a Dynamic Duo
Lingvay, I. (2017) · Endocrine Practice · doi:10.4158/ep161725.ra · Cited by 20
“No imbalance in DKA events has been observed in the pooled clinical data to date evaluating the use of canagliflozin, dapagliflozin, and empagliflozin in patients with T2DM (62,63).”
BackgroundAddressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development
Mittermayer, F., Caveney, E. J., OLIVEIRA, C. D. F., Fleming, G. A., Gourgiotis, L., Puri, M., Tai, L.-J., & Turner, J. R. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666160413115655 · Cited by 20
“Presumably the risk of DKA in T1D patients would be at least as high as that for T2D patients, but the risks related to SGLT2 inhibitors for both T1D and T2D patients are not yet clear [59].”
BackgroundCao, S., & Cao, S. (2023) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2022.12.023 · Cited by 19
A Case of Euglycemic Diabetic Ketoacidosis Following Long-term Empagliflozin Therapy
Farjo, P. D., Kidd, K. M., & Reece, J. L. (2016) · Diabetes Care · doi:10.2337/dc16-0728 · Cited by 20
“(DKA) in cases with relatively normal or mildly elevated glucose levels (euglycemic DKA [euDKA]) (1).”
BackgroundMisaghian-Xanthos, N., Shariff, A. I., Mekala, K., Fearrington, L. R., Setji, T. L., Aloi, J. A., & Buse, J. B. (2017) · Diabetes Care · doi:10.2337/dc16-2591 · Cited by 19
Sharma, A., Aziz, H., Verma, S., Abramson, B. L., Choi, R., Chua, G. L., Connelly, K. A., Honos, G. N., Mancini, G. B. J., Ramer, S. A., et al. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000892 · Cited by 19
“Finally, while an increased risk of lower limb amputations was seen in the CANVAS Program [7], a recent meta-analysis of randomized controlled studies and observation studies did not demonstrate any consistent evidence of SGLT2i exposure with an increased risk of amputation [46].”
BackgroundTravelling with heart failure: risk assessment and practical recommendations
von Haehling, S., Birner, C. M., Dworatzek, E., Frantz, S., Hellenkamp, K., Israel, C. W., Kempf, T., Klein, H. H., Knosalla, C., Laufs, U., et al. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00643-z · Cited by 20
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs
Schernthaner, G., Karasik, A., Abraitienė, A., As, A., Gaál, Z., Gumprecht, J., Janež, A., Kaser, S., Lalic, K. S., Mankovsky, B., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0920-3 · Cited by 20
Ahmed, M., McKenna, M. J., & Crowley, R. K. (2017) · Endocrine Practice · doi:10.4158/ep161447.lt · Cited by 19
New Agents for the Treatment of Type 2 Diabetes
Libianto, R., & Ekinci, E. I. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2018.11.007 · Cited by 19
Hyperglycemia management in hospitalized patients with COVID-19
Zhou, K., Al‐Jaghbeer, M. J., & Lansang, M. C. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.ccc012 · Cited by 20
Moumouni, A. N. A., Robin, P., Hillaire‐Buys, D., & Faillie, J. (2017) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12334 · Cited by 19
“Other factors could also contribute to the occurrence of ketoacidosis: food restriction, pregnancy, use of drugs such as corticosteroids, thiazides, sympathomimetic or pentamidine [11, 13, 14, 16, 19].”
BackgroundKerridge, R. K., Whyte, I. M., Prior, F. N., Luu, J., & Story, D. (2018) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1804600202 · Cited by 20
SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
Riddle, M. C., & Cefalu, W. T. (2018) · Diabetes Care · doi:10.2337/dci18-0041 · Cited by 18
“of atypical symptoms (nausea, vomiting, malaise) in the absence of significant hyperglycemia (24).”
BackgroundFukuyama, Y., Numata, K., Yoshino, K., Santanda, T., & Funakoshi, H. (2020) · Acute Medicine & Surgery · doi:10.1002/ams2.480 · Cited by 17
Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
Bobrowski, D., Kumar, R., Wu, P. E., & Lapointe‐Shaw, L. (2021) · Clinical Case Reports · doi:10.1002/ccr3.5057 · Cited by 18
Alkabbani, W., Pelletier, R., & Gamble, J. (2021) · American Journal of Epidemiology · doi:10.1093/aje/kwab052 · Cited by 18
Euglycemic Diabetic Ketoacidosis in a Patient with Cocaine Intoxication
Abdin, A. A.-A., Hamza, M., Khan, M., & Ahmed, A. (2016) · Case Reports in Critical Care · doi:10.1155/2016/4275651 · Cited by 19
Lam, K. S. L., Chow, C. C., Tan, K. C. B., Ronald, C. W., Kong, A. P. S., Tong, P. C. Y., Tsang, M. W., Chan, T. M., Tang, S. C. W., Lee, K. K., et al. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1161608 · Cited by 19
Khoo, C. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00079-x · Cited by 17
Very low carbohydrate diet and SGLT-2-inhibitor: double jeopardy in relation to ketoacidosis
Tougaard, N. H., Faber, J., & Eldrup, E. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-227516 · Cited by 16
Residual Renal Risk in Diabetic Nephropathy Despite Contemporary Therapies
Speeckaert, R., Delrue, C., & Speeckaert, M. M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15030921 · Cited by 17
“These concerns may limit SGLT2 inhibitors’ use for frail or elderly patients, patients with advanced CKD stage 4 or 5, or patients with multiple other health problems [52,53].”
Combination therapy with SGLT2 inhibitors for diabetic kidney disease
Cai, Y., Liu, X., & Xu, G. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110192 · Cited by 17
Euglycemic Diabetic Ketoacidosis
Ju, H.-H. (2024) · Critical Care Nursing Clinics of North America · doi:10.1016/j.cnc.2024.08.004 · Cited by 17
Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how? A narrative literature review
Lu, H. Y., Meyer, P., & Hullin, R. (2020) · Swiss Medical Weekly · doi:10.4414/smw.2020.20341 · Cited by 18
Tamaroff, J. G., Kilberg, M. J., Pinney, S. E., & McCormack, S. E. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.07.004 · Cited by 16
Zaina, A., Grober, Y., Ali, A., Arad, E., Golden, E., & Badarny, S. (2021) · Endocrine · doi:10.1007/s12020-021-02718-w · Cited by 17
“Treatment with SGLT-2i could be considered for diabetes management in the following categories of patients with acromegaly: rst; patients with previously diagnosed T2DM and controlled acromegaly after surgery.”
BackgroundInfluentialSGLT2i increased the plasma fasting glucagon level in patients with diabetes: A meta-analysis
Zhu, X., Lin, C., Li, L., Hu, S., Cai, X., & Ji, L. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174145 · Cited by 16
Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy
Pasqua, M., Tsoukas, M. A., & Haidar, A. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211035411 · Cited by 18
Abegaz, T. M., Diaby, V., Sherbeny, F., & Ali, A. A. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01160-8 · Cited by 15
“use of SGLT2i imposes a higher risk of DKA in patients with precipitating factors due to glycosuria [78].”
BackgroundEvaluation of empagliflozin efficacy as a promising anti-aging treatment in mice: In-vivo study
Obaid, K. A., & Fawzi, H. A. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e116184 · Cited by 17
Patakfalvi, L., Brazeau, A., & Dasgupta, K. (2018) · Primary Health Care Research & Development · doi:10.1017/s1463423618000476 · Cited by 15
“These are serious and potentially fatal complications (Rosenstock and Ferrannini, 2015).”
BackgroundSGLT-2 Inhibitors: Proliferating Indications and Perioperative Pitfalls
Madhok, J., & Vanneman, M. W. (2022) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2022.02.019 · Cited by 15
Niekerk, C. J. V., Wallace, J. R., Takata, M. C., & Yu, R. C. (2018) · BMJ Case Reports · doi:10.1136/bcr-2017-221527 · Cited by 17
Schnell, O., Valensi, P. E., Standl, E., & Ceriello, A. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.129 · Cited by 15
Chang, S., Chen, J., Chuang, Y., & Chen, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010166 · Cited by 17
“In addition, some patients may experience increased frequency of urination, which leads to lower blood pressure due to the loss of fluids; others may notice a slight increase in their cholesterol values [54].”
BackgroundLiu, H., Sridhar, V. S., Perkins, B. A., Rosenstock, J., & Cherney, D. Z. I. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01471-2 · Cited by 14
Self-citationShiau, C.-H., Tsau, L.-Y., Kao, C., Peng, Y., Bai, C., Wu, J., & Hou, W. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03789-6 · Cited by 14
CLEMENT, M. A., & Senior, P. A. (2016) · Europe PMC (PubMed Central) · Cited by 15
Patel, K. S., & Carbone, A. M. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019859323 · Cited by 15
Kraus, F. B., Kocijančić, M., Kluttig, A., & Ludwig‐Kraus, B. (2020) · Biochemia Medica · doi:10.11613/bm.2020.010707 · Cited by 16
“9 ment of blood βOHB will become even more important, since urinary ketone monitoring is not recommended in such patients (7,30).”
BackgroundRe-emergence of a forgotten diabetes complication: Euglycemic diabetic ketoacidosis
Dağdeviren, M., Akkan, T., & Ertuğrul, D. T. (2024) · Turkish Journal of Emergency Medicine · doi:10.4103/tjem.tjem_110_23 · Cited by 20
Shihab, E. M., Kadhim, H. M., & Shahooth, S. S. (2024) · Journal of Medicine and Life · doi:10.25122/jml-2023-0343 · Cited by 16
Acid-base and electrolyte disturbances in patients with diabetes mellitus
Pipeleers, L., Wissing, K. M., & Hilbrands, R. (2018) · Acta Clinica Belgica · doi:10.1080/17843286.2018.1546983 · Cited by 15
“Alcohol intake and reducing the insulin dose are precipitating events for euDKA [6].”
BackgroundGuirguis, H., Beroukhim, S., & Pham, C. D. (2022) · Clinical Medicine Insights Case Reports · doi:10.1177/11795476221090045 · Cited by 15
Euglisemic diabetic ketoacidotic coma caused by dapagliflozin
Karakaya, Z., Topal, F. E., Topal, F., Payza, U., & Akyol, P. Y. (2018) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2018.08.054 · Cited by 14
Schwartz, S. S., & Ahmed, I. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1151774 · Cited by 15
Diabetic ketoacidosis precipitated by therapy with antidiabetic agents SGLT2 inhibitors: two cases
Venkatesh, B., Moore, G., Gill, D. J., & Kelly, W. (2015) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)01318-2 · Cited by 13
Utsunomiya, K., Koshida, R., Kakiuchi, S., Senda, M., Fujii, S., Kurihara, Y., Gunji, R., & Kaku, K. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13333 · Cited by 14
Aggarwal, A., Jain, A., Sachdeva, S., & Kulairi, Z. I. (2020) · Cureus · doi:10.7759/cureus.11554 · Cited by 13
“Further, the use of exogenous insulin administered to treat ketoacidoses may have contributed to prolonging glucose excretion by compounding the glucosuric action of SGLT2 inhibitors [15].”
BackgroundBuckley, J., Riddell, M. C., Mellor, D. D., Bracken, R. M., Ross, M., Gerche, A. L., & Poirier, P. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102446 · Cited by 19
Diabetic proximal tubulopathy: Can we mimic the disease for in vitro screening of SGLT inhibitors?
Faria, J., Gerritsen, K. G. F., Nguyen, T. Q., Mihaila, S. M., & Masereeuw, R. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174378 · Cited by 14
The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes
Pafili, K., Maltezos, E. S., & Παπάνας, Ν. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1216970 · Cited by 15
“Insulin reductions, if at all, need to be very modest during co-administration [158].”
BackgroundEuglycaemic ketoacidosis in a postoperative Whipple patient using canaglifozin
Wood, T. J., Pang, A., Hallet, J. I., & Greig, P. D. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-216607 · Cited by 13
Prolonged diabetic ketoacidosis associated with canagliflozin
SLOAN, G. P., Kakoudaki, T., & Ranjan, N. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-17-0177 · Cited by 14
Euglycemic diabetic ketoacidosis
González-Castro, A., Lasa, M. O., & Alfonso, A. J. (2019) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.05.058 · Cited by 13
Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy
Papadokostaki, E., & Liberopoulos, E. N. (2019) · Case Reports in Endocrinology · doi:10.1155/2019/3901741 · Cited by 15
“These agents decrease fasting and postprandial plasma glucose levels, which in turn decrease insulin secretion [13].”
BackgroundCebada, A. B., Nattero‐Chávez, L., Díaz, S. A., Escobar-Morreale, H. F., & Luque‐Ramírez, M. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0316 · Cited by 13
Corathers, S. D., & DeSalvo, D. J. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0017 · Cited by 15
Goto, S., Ishikawa, J., Idei, M., Iwabuchi, M., Namekawa, M., & Nomura, T. (2021) · American Journal of Case Reports · doi:10.12659/ajcr.929773 · Cited by 16
“Persistent glycosuria induced by SGLT2i lowers the amount of the body glucose pool [14], and in this situation, when caloric intake decreases, the blood glucose level cannot be increased, insulin secretion is suppressed, and ketone body production is induced.”
BackgroundSodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
Vivian, E. (2015) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721715607643 · Cited by 13
“therapy).(60) In addition, because early combination therapy may be appropriate for many patients with T2DM presenting with very high A1C values, the combination of SGLT2 inhibitors with DPP-4 inhibitors or GLP-1 receptor agonists could also circumvent the potential risk of euglycemic DKA because of the propensity of…”
BackgroundResultEuglycemic diabetic ketoacidosis: The clinical concern of SGLT2 inhibitors
Benmoussa, J. A., Clarke, M., Penmetsa, A., Khine, L. Y., Leykina, L., Diaz, K. T., & Otterbeck, P. E. (2016) · Journal of Clinical and Translational Endocrinology Case Reports · doi:10.1016/j.jecr.2016.05.002 · Cited by 13
Dai, Z., Nishihata, Y., Kawamatsu, N., Komatsu, I., Mizuno, A., Shimizu, M., Toya, N., Ishimatsu, S., & Komiyama, N. (2016) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2016.10.006 · Cited by 14
“Medicines of this class are known to have several adverse effects, including euglycemic diabetic ketoacidosis (DKA), which has been reported increasingly [2].”
BackgroundLow-carbohydrate diets in type 2 diabetes
Tay, J., de Bock, M. I., & Mayer‐Davis, E. J. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30368-1 · Cited by 13
Alkatheeri, A., & Alseddeeqi, E. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-022-03347-1 · Cited by 12
“These medications, including canagliflozin, dapagliflozin, and empagliflozin, increase the risk of inducing EDKA [3, 15, 16].”
BackgroundLi, J., Zhu, C., Liang, J., Hu, J., Liu, H., Wang, Z., Guan, R., Chow, J., Yan, S., Li, L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1303694 · Cited by 13
Mori, Y., Komura, T., Adomi, M., Yagi, R., Fukuma, S., Kondo, N., Yanagita, M., Duru, O. K., Tuttle, K. R., & Inoue, K. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02478-7 · Cited by 14
“In this context, clinicians should take into account the uncertainties about benefit of SGLT2 inhibitors for CVD risk reduction versus risks of adverse events, such as ketoacidosis [14, 45], when prescribing these medications.”
Fuerlinger, A., Stockner, A., Sedej, S., & Abdellatif, M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02566-8 · Cited by 12
Review article: Ketoacidosis in the emergency department
Morton, A. (2020) · Emergency Medicine Australasia · doi:10.1111/1742-6723.13503 · Cited by 12
“1 mmol/L in 30% of cases.(13) Sixtytwo percent of cases occurred in individuals with T2DM, 27% in T1DM and 4% in individuals with latent autoimmune diabetes.”
BackgroundDiabetes and Novel Coronavirus Infection: Implications for Treatment
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00858-2 · Cited by 12
“Such concerns are due to the increased risk of diabetic ketoacidosis associated with the use of SGLT-2 inhibitors as a result of increased urinary glucose excretion, with reversal of the insulin:glucagon ratio which then precipitates ketosis [58].”
BackgroundYehya, A., & Sadhu, A. (2019) · Clinical Diabetes · doi:10.2337/cd19-0035 · Cited by 14
Metadata
- Authors
- Rosenstock, J., & Ferrannini, E.
- Affiliations
- Medical City Dallas Hospital (US)
- Istituto di Fisiologia Clinica (IT)
- Corresponding author
- Rosenstock, Julio
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-08-10
- Volume
- 38
- Issue
- 9
- Pages
- 1638-1642
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1955935325
- Cited by
- 664
- References
- 21
- Citations by year
- 2026: 23 · 2025: 33 · 2024: 55 · 2023: 36 · 2022: 43 · 2021: 68 · 2020: 89 · 2019: 79 · 2018: 67 · 2017: 75 · 2016: 77 · 2015: 18
- FWCI
- 68.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- euglycemic diabetic ketoacidosis, SGLT2 inhibitors, drug safety, type 2 diabetes, type 1 diabetes, insulin-treated patients, adverse drug reactions, risk factors, alcohol consumption, intercurrent illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.